Nothing Special   »   [go: up one dir, main page]

CY1110617T1 - Συνδυασμος αναστολεα μεταφορεα γλυκινης (glyt1) και αντιψυχωτικου για την αντιμετωπιση των συμπτωματων της σχιζοφρενιας καθως επισης η παρασκευη του και η χρηση του - Google Patents

Συνδυασμος αναστολεα μεταφορεα γλυκινης (glyt1) και αντιψυχωτικου για την αντιμετωπιση των συμπτωματων της σχιζοφρενιας καθως επισης η παρασκευη του και η χρηση του

Info

Publication number
CY1110617T1
CY1110617T1 CY20101100335T CY101100335T CY1110617T1 CY 1110617 T1 CY1110617 T1 CY 1110617T1 CY 20101100335 T CY20101100335 T CY 20101100335T CY 101100335 T CY101100335 T CY 101100335T CY 1110617 T1 CY1110617 T1 CY 1110617T1
Authority
CY
Cyprus
Prior art keywords
antipsychotic
schizophrenia
symptoms
combination
treatment
Prior art date
Application number
CY20101100335T
Other languages
English (en)
Inventor
John Allen Moyer
David Ashton
Peter Kalivas
Mark Klitenick
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1110617T1 publication Critical patent/CY1110617T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Αποκαλύπτεται ένας συνδυασμός αντιψυχωτικού και αναστολέα GlyTl. Ο συνδυασμός αντιψυχωτικού και αναστολέα GlyTl μπορεί να επιστρατευτεί στην πρόληψη και τη θεραπεία των συμπτωμάτων της σχιζοφρένιας. Επομένως αποκαλύπτονται επίσης φαρμακευτικές συνθέσεις και θεραπείες που περιλαμβάνουν ένα αντιψυχωτικό και έναν αναστολέα GlyTl για την αντιμετώπιση των συμπτωμάτων της σχιζοφρένιας.
CY20101100335T 2004-12-16 2010-04-14 Συνδυασμος αναστολεα μεταφορεα γλυκινης (glyt1) και αντιψυχωτικου για την αντιμετωπιση των συμπτωματων της σχιζοφρενιας καθως επισης η παρασκευη του και η χρηση του CY1110617T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63657504P 2004-12-16 2004-12-16
EP05849954A EP1830833B1 (en) 2004-12-16 2005-12-15 Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof

Publications (1)

Publication Number Publication Date
CY1110617T1 true CY1110617T1 (el) 2015-04-29

Family

ID=36168474

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100335T CY1110617T1 (el) 2004-12-16 2010-04-14 Συνδυασμος αναστολεα μεταφορεα γλυκινης (glyt1) και αντιψυχωτικου για την αντιμετωπιση των συμπτωματων της σχιζοφρενιας καθως επισης η παρασκευη του και η χρηση του

Country Status (12)

Country Link
US (1) US20060154919A1 (el)
EP (1) EP1830833B1 (el)
AT (1) ATE456366T1 (el)
CA (1) CA2590287A1 (el)
CY (1) CY1110617T1 (el)
DE (1) DE602005019203D1 (el)
DK (1) DK1830833T3 (el)
ES (1) ES2338346T3 (el)
PL (1) PL1830833T3 (el)
PT (1) PT1830833E (el)
SI (1) SI1830833T1 (el)
WO (1) WO2006066121A2 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032056A2 (en) * 2006-09-16 2008-03-20 Genophrenix Limited Dopamine receptor interacting proteins as markers for disease
US20090253918A1 (en) * 2006-10-02 2009-10-08 Janssen Pharmaceuticals, N.V. Novel intermediate for glyt1 inhibitor
MX2018004553A (es) * 2015-10-16 2019-04-15 Univ Northwestern Combinación farmacéutica de un antipsicótico atípico y un modulador de nmda para el tratamiento de esquizofrenia, trastorno bipolar, deterioro cognitivo y trastorno depresivo mayor.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
IL124536A (en) * 1995-12-07 2001-03-19 Daniel C Javitt Pharmaceutical compositions containing a glycine uptake antagonist
NZ508160A (en) * 1998-04-14 2004-01-30 Gen Hospital Corp Methods for treating neuropsychiatric disorders
US6476208B1 (en) * 1998-10-13 2002-11-05 Genset Schizophrenia associated genes, proteins and biallelic markers
US6426364B1 (en) * 1999-11-01 2002-07-30 Nps Allelix Corp. Diaryl-enynes
US6335681B1 (en) * 2001-02-08 2002-01-01 Teofilo Ontiveros Cruise control alert
BR0207307A (pt) * 2001-02-16 2004-08-17 Allelix Neuroscience Inc Inibidores de glyt-1
GB0314479D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
US20070105902A1 (en) * 2003-11-12 2007-05-10 Lindsley Craig W 4-Phenyl piperdine sulfonyl glycine transporter inhibitors
WO2005058317A1 (en) * 2003-12-18 2005-06-30 Glaxo Group Limited Glycine transporter-1 inhibirors
WO2005058885A2 (en) * 2003-12-18 2005-06-30 Glaxo Group Limited Piperidine derivatives and their use as glycine transporter inhibitors
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia

Also Published As

Publication number Publication date
EP1830833A2 (en) 2007-09-12
SI1830833T1 (sl) 2010-05-31
PT1830833E (pt) 2010-03-12
WO2006066121A2 (en) 2006-06-22
DE602005019203D1 (de) 2010-03-18
DK1830833T3 (da) 2010-05-17
ES2338346T3 (es) 2010-05-06
US20060154919A1 (en) 2006-07-13
EP1830833B1 (en) 2010-01-27
PL1830833T3 (pl) 2010-06-30
WO2006066121A3 (en) 2006-08-10
ATE456366T1 (de) 2010-02-15
CA2590287A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
ECSP14019136A (es) Combinaciones farmacéuticas de un antagonista del receptor de angiotensina y un inhibidor de endopeptidasa neutra (nep)
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
DE602005026556D1 (de) Zusammensetzung zur proteasomhemmung
CY1109523T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
EA200870086A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
NO20092417L (no) Kombinasjon av IAP-inhibitorer og FLT3-inhibitorer
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
WO2007140317A3 (en) Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
CY1110617T1 (el) Συνδυασμος αναστολεα μεταφορεα γλυκινης (glyt1) και αντιψυχωτικου για την αντιμετωπιση των συμπτωματων της σχιζοφρενιας καθως επισης η παρασκευη του και η χρηση του
NO20084190L (no) Anvendelse av VX-702 til behandling av revmatoid artritt
EA200702201A1 (ru) Рофлумиласт для лечения лёгочной гипертензии
WO2006057997A3 (en) Plasmin-inhibitory therapies
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori